Cargando...
Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma
BACKGROUND: We conducted a cost-effectiveness analysis of brentuximab vedotin for the treatment of relapsed and refractory Hodgkin lymphoma (hl) in the post–autologous stem-cell transplantation (asct) failure period, from the perspective of the Canadian health care payer. METHODS: We developed a dec...
Gardado en:
| Publicado en: | Curr Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Multimed Inc.
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5330640/ https://ncbi.nlm.nih.gov/pubmed/28270727 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.24.3369 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|